Atomico manages funds supporting early-stage and growth-stage European technology companies.
The Series B round was led by Autodesk with backing from Lockheed Martin and British Patient Capital.
"When people think of manufacturing, they tend to think of robotic car factories, and don’t realise that the industry is dominated by craft processes reliant on dwindling expert knowledge. This makes it incredibly complex to get things made, stifling the pace of innovation,"
The Series A round was led by Atomico with participation from notable angel investors and existing backers.
"This is the first time we have seen a tool really designed with the needs of business owners in mind, empowering them with access to everything they need in one place, in a world where most teams are still forced to buy multiple fragmented solutions, work in silos, or pay high legal fees to outside experts"
The investment round was led by Atomico and will support international expansion.
"The fertility care model as we know it today is broken because the gap between those who want access to fertility treatments and those who can afford access is greater than ever. Three out of four people who seek fertility treatment never start because they believe the financial burden would be too large,"
The seed round was led by Speedinvest with participation from Atomico and notable angels.
"In a world where you order food in a tap, hail taxis in an instant, and swipe to date, there’s something oddly exhilarating about being forced to wait. Before digital cameras you had no idea what you captured. The suspense of not knowing paired with seeing your snaps for the first time is a powerful feeling. We’ve re-created that experience and made it social"
The Series B round was led by Lakestar with backing from institutional investors and venture funds to support team growth and product expansion.
"accuRx’s product has reinvigorated communication with our patients, enabling a better relationship between GPs and patients, which has ultimately led to better care provision. Our patients now have the confidence that they’re getting speedy and accurate responses from our team, and the use of regular Florey questionnaires to gather more information from our patients has been transformative for clinical record keeping and the care we provide. We’re thrilled that accuRx has received funding which will enable it to expand its primary care product set, some of which we’re trialling at the moment. We’re also excited about accuRx’s progress into secondary care as better interaction between primary and secondary care is a huge step forward for safer and more effective patient care."
